Rep. Lisa C. McClain Sells Off Shares of Illumina, Inc. (NASDAQ:ILMN)

Posted by Bonnie Powley on Nov 28th, 2025

Representative Lisa C. McClain (R-Michigan) recently sold shares of Illumina, Inc. (NASDAQ:ILMN). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Illumina stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $129.81 on Friday. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $153.06. The firm has a market capitalization of $19.83 billion, a price-to-earnings ratio of 16.43, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The firm has a 50 day moving average of $107.40 and a 200 day moving average of $98.82.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the firm earned $1.14 earnings per share. The company’s quarterly revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Hedge Funds Weigh In On Illumina

Several hedge funds have recently modified their holdings of the stock. Rise Advisors LLC grew its stake in Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 224 shares in the last quarter. Parkside Financial Bank & Trust grew its position in shares of Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares in the last quarter. Quent Capital LLC purchased a new position in shares of Illumina during the third quarter valued at about $29,000. Quarry LP bought a new stake in shares of Illumina in the third quarter worth about $32,000. Finally, Aster Capital Management DIFC Ltd purchased a new stake in shares of Illumina in the third quarter worth about $33,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 500 shares of Illumina stock in a transaction on Monday, November 3rd. The shares were acquired at an average price of $122.13 per share, with a total value of $61,065.00. Following the purchase, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. The trade was a 4.16% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ILMN shares. Stephens set a $110.00 price target on Illumina and gave the stock an “overweight” rating in a research report on Monday, August 4th. TD Cowen increased their target price on shares of Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a report on Friday, October 31st. Daiwa Capital Markets cut shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price on the stock. in a research note on Tuesday, August 12th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Illumina in a research report on Wednesday, October 8th. Finally, Evercore ISI increased their price objective on shares of Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Five analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Illumina presently has a consensus rating of “Hold” and an average target price of $115.00.

View Our Latest Report on ILMN

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Illumina

(Get Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.